First Bank and Trust decreased its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 22.1% in the

Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy gr

Gilead Sciences is upgraded to a cautious 'Buy' after Q2/26, supported by robust revenue growth and

Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 m

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Hi

Total Product Sales (excluding Veklury): $7.6 billion, up 10% year-over-year.Total Product Sales (in

Please replace the release with the following corrected version due to a change in the "PRODUCT SALE

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corr

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Gilead Sciences NASDAQ: GILD reported second-quarter 2026 base business sales growth of 10% year ove

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter en

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus

LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.

On August 4, 2026, Gilead Sciences Inc (GILD) released its 8-K filing detailing financial results fo

The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19

Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led ​by double-digit gains

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced tod

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfiz

California's highest court ​ruled on Monday that manufacturers of drugs that are considered safe do

California's highest court on Monday ruled in favor of Gilead Sciences , in a case addressing whethe

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences

Avidity Partners Management LP purchased a new position in Gilead Sciences, Inc. (NASDAQ: GILD) duri

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C comb

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppressio

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

Nasdaq jumps 1.6% to record highs Friday as semiconductor rally and stronger-than-expected April pay

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX

After three straight rebound sessions, the software selloff resumed Wednesday, with the iShares Tech

Investors are anticipating reports from Robinhood, Pinterest, Rivian and more. Here's a look at

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding t

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activi

Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced G

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from Pres

https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-r

Insights from strategists and analysts can greatly influence market sentiment and investment strateg

U.S.